If you would like to inquire about all open trials, please contact 919.684.3401.
2 trials identified.
An Open Label, Expanded Access Protocol Using (131)I-Metaiodobenzylguanidine (I-MIBG) Therapy in Patients with Refractory Neuroblastoma Phase: Other Sponsor: OTHER Principal Investigator: Michael Armstrong Contact: Dr. Michael Armstrong Phone: 919.684.3401 Reference Number: 00012332 View this trial at ClinicalTrials.gov
ANBL1221 A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
Phase: Phase II Sponsor: Cooperative Group Initiated Principal Investigator: Susan Kreissman Contact: Dr. Susan Kreissman Phone: 919.684.3401 Reference Number: 00044246 View this trial at ClinicalTrials.gov
Ways To Give
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.